Nemaura Medical to Present at the Planet MicroCap Showcase 2022
April 25 2022 - 8:30AM
Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company
focused on developing and commercializing wearable diagnostic
devices and supporting personalized lifestyle coaching programs,
announces today that CEO Dr. Faz Chowdhury will present virtually
at the Planet MicroCap Showcase 2022. The conference is being held
on May 3 – 5, 2022 at The Bally’s Hotel & Casino in Las Vegas,
NV.
Presentation Date: |
May 4, 2022 |
Time: |
9:00am Pacific Time |
Webcast
Link: |
https://www.webcaster4.com/Webcast/Page/2862/45042 |
Dr.Chowdhury will be available for one-on-one meetings. To
request a meeting and to register for the conference, click here:
https://planetmicrocapshowcase.com/signup
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology
company developing and commercializing wearable diagnostic devices.
The company is currently commercializing sugarBEAT® and
proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device,
is a non-invasive and flexible continuous glucose monitor (CGM)
providing actionable insights derived from real time glucose
measurements and daily glucose trend data, which may help people
with diabetes and pre-diabetes to better manage, reverse, and
prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S.
FDA. proBEAT™ combines non-invasive glucose data processed
using artificial intelligence and a digital healthcare subscription
service and has been launched in the U.S. as a general wellness
product as part of its BEAT®diabetes program that is currently
undergoing pilot studies.
Additionally, Nemaura has launched Miboko, a new
metabolic health and well-being program using a non-invasive
glucose sensor along with an AI mobile application that helps a
user understand how certain foods and lifestyle habits can impact
one’s overall metabolic health and well-being. Nemaura believes
that up to half the population could benefit from a sensor and
program that monitors metabolic health and well-being.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit
www.NemauraMedical.com.
Contact:
Jules AbrahamCORE IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024